SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares plummeted following a disappointing fiscal second-quarter earnings report, where a revenue miss and significant cuts to full-year guidance fueled concerns over weakening demand in North America and an overall brand decline. The community is heavily polarized, with many retail traders viewing the sell-off as a collapse of a "fad" brand and others debating whether the stock's sharp decline to multi-year lows offers a deep value buying opportunity.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors react to a double beat in its latest earnings report, with the company raising its revenue outlook and ARR guidance. While many traders see this as a strong fundamental turnaround and potential for a short squeeze, others remain skeptical, citing concerns over growth acceleration and valuation, resulting in high volatility and intense debate among market participants.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs shares experienced significant volatility and a decline following their quarterly report, as traders debated the impact of softer guidance and the company's backlog position despite a revenue beat. The community remains divided between those viewing the pullback as a buying opportunity for long-term growth and those skeptical of the company's guidance and management.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is experiencing high volatility as traders react to its fiscal fourth-quarter results, which featured a revenue beat but decelerating growth and cautious forward guidance. The community remains divided, with many expressing frustration over the company's guidance and management, while others view the pullback as a buying opportunity given the firm's role in the zero-trust security sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is rallying as investors anticipate the company's highly anticipated Cybercab launch event, leading to a high-volume debate over whether the stock will face a "sell the news" correction or continue its upward momentum. While bullish traders emphasize the potential of the autonomous technology and potential gamma squeezes, many participants warn that the event is already priced in, citing historical patterns of post-event price declines.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is seeing heightened volatility and intense debate among traders following the company's recent Bitcoin acquisitions and ongoing share dilution, which some view as a long-term drag while others see as a strategic play for future growth. The stock's price action remains closely tied to Bitcoin's momentum, with strong disagreement between bulls anticipating a continued rally and bears pointing to technical resistance and macro-related risks.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is trending as traders debate the company's long-term viability in an AI-driven market, with many expressing skepticism about its moat against generative AI competitors. While some investors view the current price as an attractive entry for a recovery, others remain convinced the stock is a value trap that could see significant further downside.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as shares rally following a series of Wall Street analyst upgrades, including a positive rating shift and a price target hike from Morgan Stanley. Investors are reacting to the company's diversification beyond retail brokerage, specifically highlighting growth in its prediction markets, international crypto infrastructure, and the Robinhood Chain.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as traders weigh the impact of an upsized $500 million share repurchase program, with investors debating whether the buybacks signal deep undervaluation and confidence in growth or merely serve as a temporary mechanism during OTC trading. While some community members view the company's expansion and cash position as signs of an impending relisting and long-term upside, others remain skeptical, citing historical volatility, concerns over institutional control, and persistent distrust in Chinese ADRs.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella shares are facing volatility as traders debate the company's valuation and long-term potential as a "physical AI" and edge-computing play versus concerns over quarterly revenue misses and supply chain headwinds. While some investors are bullish on the company's edge AI and automotive design wins, others are expressing frustration with recent negative price action and lingering uncertainty following earnings results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics is trending as investors react to the company's withdrawn proposal for a $500 million stock offering, coupled with significant open-market insider purchases by the Co-CEOs. The community sentiment remains divided between concerns over dilution and enthusiasm for the company's clinical pipeline, specifically the upcoming FDA PDUFA date for its cancer treatment, ivonescimab.

The increase is being attributed to positive data from the Phase III HARMONi-2 study, in which ivonescimab demonstrated a statistically significant overall survival benefit compared to pembrolizumab in patients with PD-L1-positive non-small cell lung cancer. Traders are also citing high trading volume and the potential for a short squeeze as contributing factors to the price momentum.

Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday

U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.read more...

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or...

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer  

Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.

Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim

Equity

Akeso reported positive late-stage data for Ivonescimab, a drug that Summit Therapeutics holds the rights to develop and sell outside China.

Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy

Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.read more...

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.read more...

Futures Flat Ahead Of Key PCE Report, Nvidia Earnings

Futures Flat Ahead Of Key PCE Report, Nvidia Earnings

 Stock futures are are flat and Treasuries slipped while oil stumbled heading into today's PCE report and NVDA earnings. As of 8:00am ET, S&P Futures are unchanged and Nasdaq futures drop 0.2% as?NVDA and MRVL both rise 0.2% with...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million.
Summit Therapeutics (NASDAQ:SMMT) stock roseread more...

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Extremely Bullish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Stocktwits

Stocktwits Polls

Speculation is intensifying that the company's strong oncology platform and clinical success could trigger a premium acquisition by Big Pharma.

Optimism surrounds the ivonescimab clinical data as traders compare its efficacy directly against major industry incumbents.

The upcoming FDA decision in mid-November serves as the primary binary event traders are positioning for with heavy options volume.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SMMT Summit Therapeutics Inc

Fundamentals

Latest SMMT News